ATRA for adults with immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a medicine called ATRA (a form of vitamin A) to see if it can help adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing bleeding and bruising. It is for people who have already tried standard treatments without lasting success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with primary ITP.
- Your platelet counts have been low (below 30) on at least two tests, and no count above 35 in the last 2 weeks.
- You have tried at least one standard treatment (like steroids or IVIG) and it didn't work, stopped working, or caused side effects.
- You are not pregnant, planning to become pregnant, or breastfeeding.
- You do not have active infections (like hepatitis, HIV, or tuberculosis) or a history of certain cancers or organ transplants.
- Your liver, kidney, and blood counts are within acceptable levels for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests a combination of two medicines (atorvastatin and N-acetylcysteine) added to romiplostim for adults with immune thrombocytopenia (ITP) that hasn't responded well to steroids. The goal is to help raise your platelet count and reduce bleeding risk.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.